A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator’s Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
France, Germany, Spain, Netherlands, Italy, Belgium, Greece
Condition studied
High-risk Non-muscle-invasive Bladder
Cancer with Susceptible FGFR Alterations
Investigational medicinal product(s)
JNJ-42756493MITOMYCINGEMCITABINE
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
DFS
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.